Study That Tests AD109 in Patients Taking GLP-1 Drugs

NCT06400615 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety of AD109 in people with obstructive sleep apnea who are also taking GLP-1 medications.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 40 people

Who can join Ages 18–75 · all sexes

Timeline Started 2024-05 · est. completion 2024-12

Where 4 sites · United States

What this study is testing ClinicalTrials.gov NCT06400615 ↗

Description as written by the study sponsor.

Phase 2 Safety, Efficacy and, Tolerability of Fixed Dose Combination of Aroxybutynin/Atomoxetine (AD109) in Obstructive Sleep Apnea Patients Taking Tirzepatide, Semaglutide or Liraglutide

Treatments tested

AD109 Drug

Oral administration at bedtime

Main thing measured	Primary Objective (Adverse Events)
Sponsor	Apnimed
Conditions studied	OSA
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06400615 ↗